Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions

被引：15
|
作者：
Ambati, Srikanth R. [1 ]
Slotkin, Emily K. [1 ]
Chow-Maneval, Edna [2 ]
Basu, Ellen M. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
[2] Ignyta, San Diego, CA USA
来源：
JCO PRECISION ONCOLOGY | 2018年 / 2卷
基金：
美国国家卫生研究院;
关键词：
LYMPHOMA KINASE ALK; CLINICAL-RESPONSE; PAN-TRK; INHIBITOR; SARCOMA;
D O I：
10.1200/PO.18.00095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1 / 6
页数：6
相关论文
共 50 条
  • [21] Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
    A. S. Mansfield
    Z. Wei
    R. Mehra
    A. T. Shaw
    C. H. Lieu
    P. M. Forde
    A. E. Drilon
    E. P. Mitchell
    J. J. Wright
    N. Takebe
    E. Sharon
    D. Hovelson
    S. Tomlins
    J. Zeng
    K. Poorman
    N. Malik
    R. J. Gray
    S. Li
    L. M. McShane
    L. V. Rubinstein
    D. Patton
    P. M. Williams
    S. R. Hamilton
    B. A. Conley
    C. L. Arteaga
    L. N. Harris
    P. J. O’Dwyer
    A. P. Chen
    K. T. Flaherty
    npj Precision Oncology, 6
  • [22] Acral Lentiginous Melanoma Harboring a ROS1 Gene Fusion With Clinical Response to Entrectinib
    Couts, Kasey L.
    McCoach, Caroline E.
    Murphy, Danielle
    Christiansen, Jason
    Turner, Jacqueline
    Lewis, Karl D.
    Robinson, William A.
    Doebele, Robert C.
    JCO PRECISION ONCOLOGY, 2017, 1 : 1 - 7
  • [23] Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
    Mansfield, A. S.
    Wei, Z.
    Mehra, R.
    Shaw, A. T.
    Lieu, C. H.
    Forde, P. M.
    Drilon, A. E.
    Mitchell, E. P.
    Wright, J. J.
    Takebe, N.
    Sharon, E.
    Hovelson, D.
    Tomlins, S.
    Zeng, J.
    Poorman, K.
    Malik, N.
    Gray, R. J.
    Li, S.
    McShane, L. M.
    Rubinstein, L., V
    Patton, D.
    Williams, P. M.
    Hamilton, S. R.
    Conley, B. A.
    Arteaga, C. L.
    Harris, L. N.
    O'Dwyer, P. J.
    Chen, A. P.
    Flaherty, K. T.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [24] Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
    Desai, Ami, V
    Robinson, Giles W.
    Gauvain, Karen
    Basu, Ellen M.
    Macy, Margaret E.
    Maese, Luke
    Whipple, Nicholas S.
    Sabnis, Amit J.
    Foster, Jennifer H.
    Shusterman, Suzanne
    Yoon, Janet
    Weiss, Brian D.
    Abdelbaki, Mohamed S.
    Armstrong, Amy E.
    Cash, Thomas
    Pratilas, Christine A.
    Corradini, Nadege
    Marshall, Lynley, V
    Farid-Kapadia, Mufiza
    Chohan, Saibah
    Devlin, Clare
    Meneses-Lorente, Georgina
    Cardenas, Alison
    Hutchinson, Katherine E.
    Bergthold, Guillaume
    Caron, Hubert
    Maneval, Edna Chow
    Gajjar, Amar
    Fox, Elizabeth
    NEURO-ONCOLOGY, 2022, 24 (10) : 1776 - 1789
  • [25] RET, ROS1 and ALK fusions in lung cancer
    Kengo Takeuchi
    Manabu Soda
    Yuki Togashi
    Ritsuro Suzuki
    Seiji Sakata
    Satoko Hatano
    Reimi Asaka
    Wakako Hamanaka
    Hironori Ninomiya
    Hirofumi Uehara
    Young Lim Choi
    Yukitoshi Satoh
    Sakae Okumura
    Ken Nakagawa
    Hiroyuki Mano
    Yuichi Ishikawa
    Nature Medicine, 2012, 18 : 378 - 381
  • [26] RET, ROS1 and ALK fusions in lung cancer
    Takeuchi, Kengo
    Soda, Manabu
    Togashi, Yuki
    Suzuki, Ritsuro
    Sakata, Seiji
    Hatano, Satoko
    Asaka, Reimi
    Hamanaka, Wakako
    Ninomiya, Hironori
    Uehara, Hirofumi
    Choi, Young Lim
    Satoh, Yukitoshi
    Okumura, Sakae
    Nakagawa, Ken
    Mano, Hiroyuki
    Ishikawa, Yuichi
    NATURE MEDICINE, 2012, 18 (03) : 378 - 381
  • [27] Entrectinib, an oral pan-Trk, ROS1 and ALK inhibitor in TKI-naIve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results
    Drilon, Alexander
    De Braud, Filippo G.
    Siena, Salvatore
    Ou, Sai-Hong I.
    Patel, Manish
    Ahn, Myung-Ju
    Lee, Jeeyun
    Bauer, Todd M.
    Farago, Anna F.
    Liu, Stephen V.
    Reddinger, Natasha
    Patel, Rupal
    Luo, David
    Maneval, Edna Chow
    Multani, Pratik S.
    Doebele, Robert C.
    Shaw, Alice T.
    CANCER RESEARCH, 2016, 76
  • [28] Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients
    Novaes, Lazaro Antonio Campanha
    da Silva, Luciane Sussuchi
    de Marchi, Pedro
    Cavagna, Rodrigo de Oliveira
    de Paula, Flavia Escremim
    Zanon, Maicon Fernando
    Evangelista, Adriane Feijo
    da Silva, Eduardo Caetano Albino
    Silva, Vinicius Duval da
    Leal, Leticia Ferro
    Reis, Rui Manuel
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 292 - 303
  • [29] Inflammatory myofibroblastic tumor of bone harboring an ALK gene amplification
    Wang, Kai
    Guo, Rongjun
    Siegal, Gene P.
    Wei, Shi
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (09)
  • [30] STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with advanced solid tumors and primary CNS tumors, with or without TRK, ROS1, or ALK fusions
    Desai, Ami V.
    Brodeur, Garrett M.
    Foster, Jennifer
    Shusterman, Suzanne
    Sabnis, Amit J.
    Macy, Magaret
    Wetmore, Cynthia
    Basu, Ellen
    Hornby, Zachary
    Esquibel, Vanessa
    Maneval, Edna Chow
    Multani, Pratik S.
    Fox, Elizabeth
    CANCER RESEARCH, 2017, 77
12345